Clinical Trial Update: Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating whether adding autologous stem cell transplant to rituximab improves outcomes in patients with minimal residual disease–negative mantle…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Rituxan (rituximab)

Snippet

Sponsor: ECOG-ACRIN Cancer Research Group | Conditions: Mantle Cell Lymphoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING